Hepatitis C Vaccines, Antibodies and T Cells
- 1Université de Montréal, Canada
The development of vaccines that protect against persistent hepatitis C virus (HCV) infection remain a public health priority. The broad use of highly effective direct acting antivirals (DAAs) is unlikely to achieve HCV elimination without vaccines that can limit viral transmission. Two vaccines targeting either the antibody or the T cell response are currently in preclinical or clinical trials. Next generation vaccines will likely involve a combination of these two strategies. This review summarizes the state of knowledge about the immune protective role of HCV-specific antibodies and T cells and the current vaccine strategies. In addition, it discusses the potential efficacy of vaccination in DAA-cured individuals. Finally, it summarizes the challenges to vaccine development and the collaborative efforts required to overcome them.
Keywords: Hepatitis C, Vaccines, Antibodies, T cells, Reinfection
Received: 16 Apr 2018;
Accepted: 14 Jun 2018.
Edited by:Thomas F. Baumert, INSERM U1110 Institute de Recherche sur les Maladies Virales et He ́patiques, France
Reviewed by:Georg Lauer, Massachusetts General Hospital, Harvard Medical School, United States
Tobias Boettler, Universitätsklinikum Freiburg, Germany
Copyright: © 2018 Shoukry. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Dr. Naglaa H. Shoukry, Université de Montréal, Tour Viger, Local R09.414, 900 rue St-Denis, Montreal, H2X 0A9, Quebec, Canada, firstname.lastname@example.org